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When a new class of drug reaches the market, clini-cians need to learn how to use it. No matter how well 
done the clinical trials with the new drug, there is no sub-
stitute for real world experience. However, it is useful to 
also consider the likely consequences of the biochemical, 
mechanistic, and pharmacological features of new drugs 
and how those might be similar to or different from the 
existing agents.
Non–vitamin K antagonist oral anticoagulants (NOACs), 
also referred to as direct oral anticoagulants, have been rap-
idly adopted because of the well-recognized difficulties 
in managing anticoagulation with vitamin K antagonists 
(VKAs), such as warfarin. VKAs were first promoted as 
rodenticides, but warfarin was subsequently introduced as an 
anticoagulant under the trade name Coumadin.1 It achieved 
wide acceptance after 1955 when it was administered as an 
anticoagulant to President Eisenhower after a heart attack. 
The first randomized clinical trial of a VKA was published in 
1960, showing it to be highly effective in preventing recur-
rence or extension of pulmonary embolism.2 VKAs have 
continued to be widely used up through the present time 
because until recently they were the only orally active anti-
coagulants available.
Clinical trials show the NOACs as a group to be at least as 
effective in preventing thrombosis as warfarin for most indi-
cations and less likely to be associated with serious bleeding 
complications.3–5 They are also more convenient for doctor 
and patient—no routine monitoring and little need for dose 
adjustment. This is because the pharmacokinetic properties of 
NOACs are more predictable and there are fewer food and 
drug interactions than with the VKAs. Of course, the NOACs 
are not perfect drugs. Like all anticoagulants to date, they 
are associated with a risk of bleeding. They are also much 
more expensive than VKAs, blood levels are more difficult to 
assay when needed, and agents to reverse their anticoagulant 
effects are less readily available.6 Their characteristics have 
been reviewed many times in the literature (See, for example, 
the following references 7–10). There are also several ways in 
which the NOACs are mechanistically different from VKAs 
that are not so widely appreciated or discussed. The goal of 
this brief review is to point out some of these characteristics 
and highlight their potential clinical implications.
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Abstract—The biochemical properties of the non–vitamin K antagonist oral anticoagulants (NOACs) and their differences from 
the mechanism of action of vitamin K antagonists contribute to their properties as anticoagulants. These properties include 
as follows: (1) Inhibiting a single protease is much less effective at inhibiting coagulation than is inhibiting at multiple steps. 
Thus, the dose–response relationship between NOAC level and intensity of anticoagulation is shallower and more linear than 
that of vitamin K antagonists. This partially accounts for the greater safety of NOACs than vitamin K antagonists reported 
in some studies. (2) Because they are small molecules, NOACs can reach their target proteases in locations that plasma 
protease inhibitors, such as antithrombin, cannot. (3) NOACs compete with substrates for binding at the active site of the 
target protease and that binding is reversible. When the drug level falls, the drug dissociates from its target, and protease 
activity is restored. Thus, there is the possibility of a rebound in procoagulant activity if the drug is abruptly terminated. (4) 
The effects of a NOAC can be overcome by increasing the amount of substrate available for the target protease or the amount 
of protease produced. This property may contribute to the safety of NOACs and their potential reversibility by coagulation 
factor concentrates. The biochemical properties of NOACs contribute to their suitability for use in conditions that require a 
predictable moderate degree of anticoagulation when administered orally at a consistent dose. Their effects can be overcome 
by a sufficiently strong procoagulant stimulus. This characteristic likely contributes to their generally reduced risk of serious 
bleeding. However, they are not well suited for use in settings that require a profound degree of anticoagulation.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2017;37: 
1812-1818. DOI: 10.1161/ATVBAHA.117.306995.)
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What Is So Different About NOACs?
NOACs Are Inhibitors Rather Than Inactivators
The NOACs are orally active small molecule inhibitors (<500 
MW) that each has high specificity and relatively high affinity 
for a single coagulation protease. At the present time, there is 1 
such inhibitor of thrombin on the market, dabigatran (Pradaxa, 
Boehringer Ingelheim) and 4 factor Xa (FXa) inhibitors (riva-
roxaban [Xarelto, Bayer Pharma/Janssen Pharmaceuticals], 
apixaban [Eliquis, Bristol-Myers Squibb/Pfizer], edoxaban 
[Savaysa/Lixiana, Daiichi Sankyo], and betrixaban [Bevyxxa, 
Portola]). It is certainly possibly that in the future there will 
be direct inhibitors of other proteases as well, such as FIXa 
or FXIa.
The NOACs bind at the active sites of coagulation 
enzymes. Thus, each competes for binding at the active site 
with substrates of its target protease. Small molecule sub-
strates of the coagulation proteases, such as the chromogenic 
substrates used in activity assays, usually bind solely at the 
active site. Such interactions occur in solution and fit neatly 
into the framework taught in undergraduate biochemistry 
class. NOACs are competitive inhibitors in this scenario: 
substrate and inhibitor bind to the same site on the enzyme, 
both cannot be bound simultaneously, and the presence of the 
inhibitor affects the Km, but not the Vmax of the reaction. 
Sadly for those of us who are not kineticists, the physiologi-
cally relevant reactions of the coagulation proteases are not 
that simple. Most of the coagulation proteases act in concert 
with a protein cofactor and on a cellular surface rather than 
in solution. The biological substrates of coagulation prote-
ases are themselves large proteins. These macromolecular 
substrates bind not only at the enzyme’s active site but also 
at additional sites (called exosites) away from the active site. 
They may also bind to the membrane surface on which the 
active complex is assembled. Many of these macromolecular 
substrates are also cleaved at more than 1 site. For example, 
prothrombin is activated by FXa in complex with its cofactor 
FVa (prothrombinase complex). When this complex is assem-
bled on the surface of activated platelets, prothrombin binds 
and is cleaved first at Arg-271 followed by cleavage at Arg-
320, without dissociating from the complex.11 Interestingly, 
when prothrombinase complexes assemble on synthetic phos-
pholipid vesicles or red blood cells, prothrombin is cleaved 
first at Arg-320.12 The resulting intermediate (meizothrombin) 
dissociates from the surface, rebinds, and is cleaved at Arg-271 
to produce thrombin. In summary, the binding and activation 
of prothrombin by FXa/FVa is complex, and it is influenced 
by the lipid surface and involves interactions with multiple 
sites on FXa. Therefore, it should come as no surprise that the 
precise kinetic effects of a small molecule FXa inhibitor on 
such an intricate process are also not straightforward and are 
beyond the scope of this review.
The fact that NOACs interact with the active site of the tar-
get protease means that binding only occurs after the zymogen 
form of the target protease has been activated by the coagula-
tion reactions. By contrast, VKAs reduce the effective plasma 
levels of all of the vitamin K–dependent coagulation zymo-
gens. They do this by interfering with post-translational car-
boxylation of specific glutamic acid residues that are critical 
for activity. While the proteins are synthesized, their undercar-
boxylated forms do not have normal activity. VKAs thereby 
reduce the levels of active proteases that can be produced in 
response to a procoagulant stimulus rather than inhibiting 
them after they have been activated.
The NOACs are inhibitors of coagulation factors rather 
than inactivators. The primary physiological regulators of 
factors IXa, Xa, and thrombin are the plasma serine prote-
ase inhibitors (SERPINs) antithrombin and α-1-proteinase 
inhibitor, with contributions from the non-SERPIN inhibitor 
α-2-macroglobulin. Like the NOACs, SERPINS and α-2-
macroglobulin only interact with coagulation factors after 
they have been activated to functional proteases. However, 
SERPINS and α-2-macroglobulin inactivate their target pro-
teases by formation of complexes that are essentially irrevers-
ible.13,14 By contrast, the NOACs form reversible complexes 
with the active site of their target proteases.
NOACs Inhibit a Single Protease Instead of Many
By contrast to the highly specific NOACs, warfarin and 
other VKAs interfere with the γ carboxylation of all vitamin 
K–dependent coagulation factors. In effect, VKAs lower the 
plasma level of multiple procoagulant factors (FII, VII, IV, 
and X), as well as the antithrombotic factors protein C, S, and 
Z.15 Because multiple factors are affected, the net effect of any 
given dose or plasma level of a VKA is difficult to predict. By 
contrast, with the direct inhibitors, the relationship between 
the plasma level of a direct inhibitor and the degree of prote-
ase inhibition is much more predictable.
The unpredictability of VKAs is also because of vari-
ability in absorption and metabolism of the drug, as well as 
variability in baseline levels of coagulation factors between 
individuals. Because of the many variables that can impact the 
degree of anticoagulation by VKAs and their narrow therapeu-
tic window, routine laboratory monitoring is necessary. The 
prothrombin time has been used empirically and standardized 
as a measure of the overall VKA effect in an individual.16
The other anticoagulants backed by extensive clinical 
experience are unfractionated heparin (UFH) and low molecu-
lar weight heparins. Neither UFH nor low molecular weight 
heparins directly inhibits coagulation proteases. Both accel-
erate antithrombin inactivation of proteases. UFH acceler-
ates inactivation of all of the coagulation proteases to some 
degree. Low molecular weight heparins primarily accelerate 
inactivation of Fxa but can also enhance inactivation of other 
factors to lesser extents. In all cases, even after the heparins 
are cleared from the plasma, the proteases do not dissociate 
from antithrombin and regain activity.
Nonstandard Abbreviations and Acronyms
FXa factor Xa
NOAC non–vitamin K antagonist oral anticoagulant
SERPIN serine protease inhibitor
TF tissue factor
UFH unfractionated heparin
VKA vitamin K antagonist
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Similar to VKA’s, the effect of UFH in any given individ-
ual is unpredictable. Thus, the activated partial thromboplastin 
time has been used empirically to monitor the net anticoagu-
lant effect of UFH. It should be noted that the prothrombin 
time and activated partial thromboplastin time are prolonged 
to a much great degree by drugs that inhibit multiple proteases 
(VKAs and UFH) than by drugs that only inhibit 1 protease 
(NOACs, low molecular weight heparins, fondaparinux, and 
bivalirudin). Fondaparinux is a pentsaccharide that can be 
thought of as the lowest molecular weight heparin. It binds 
to antithrombin and enhances its ability to inhibit FXa, with 
little ability to enhance antithrombin inhibition of other pro-
teases. Like other heparin-like agents, it must be administered 
parenterally. Bivalirudin is a specific direct inhibitor of throm-
bin that also must be administered parenterally. None of these 
specific inhibitors prolong the common prothrombin time and 
activated partial thromboplastin time assays to a significant 
and predictable degree. Thus, they all require more special-
ized and expensive testing to assay.
How Do NOACs Exert Antithrombotic Effects?
There exists a considerable body of evidence supporting the 
premise that the amount and pattern of thrombin generated 
in response to a procoagulant signal reflect the adequacy of 
hemostatic function17–19 and the risk of thrombosis.20 Several 
assays, both commercial and homemade, have been used to 
assess the pattern of thrombin generation in response to a pro-
coagulant signal using platelet-rich or platelet-poor plasma. 
In these assays, the level of thrombin activity is assessed as 
the amount of a chromogenic or fluorogenic substrate that is 
cleaved over the course of the reactions. This can be moni-
tored continuously by initiating the coagulation reactions in 
the presence of the thrombin substrate or by taking samples 
from the reaction mixture and transferring them into a solu-
tion of the thrombin substrate. Although thrombin generation 
assays are not yet practical or sufficiently standardized for 
routine clinical use, they have been widely used as a research 
tool. However, it is not clear which parameter(s) derived from 
thrombin generation assays best predict either hemostasis or 
thrombosis. At least in theory, there should be a sweet spot in 
the parameters of thrombin generation that reflects a state in 
which the risk of thrombosis is minimized while the ability to 
attain hemostasis is optimized.
In contrast to their effects on the prothrombin time and acti-
vated partial thromboplastin time assays, the effects of NOACs 
on thrombin generation can be readily demonstrated. However, 
they are not as predictable as one might expect. The response 
of thrombin generation parameters to increasing NOAC con-
centrations is certainly not linear and seems to show threshold 
effects in some cases. The points of inhibition by NOACs are 
often represented in a coagulation cascade model (Figure 1). 
Viewed in this context, it seems that both FXa and thrombin 
(FIIa) inhibitors should reduce the effective amount of throm-
bin available to clot fibrinogen. Although this view is clear and 
useful for illustrating the different proteases inhibited by these 
agents, the situation in vivo is more complex and subtle than 
represented in this model. A cell-based model of coagulation 
better represents hemostatic coagulation in vivo. In this model, 
the process of thrombin generation is viewed as occurring on 
cell surfaces in overlapping phases (Figure 2) rather than as a 
continuous cascade of thrombin generation.
In a cell-based model,22 the initiation phase of blood coag-
ulation results in production of small amounts of thrombin 
on tissue factor (TF)–bearing cells. TF is normally separated 
Figure 1. Targets of non–vitamin K antagonist oral anticoagulants 
(NOACs) in the cascade model of coagulation. FXa indicates fac-
tor Xa; HK, high-molecular weight kininogen; PK, prekallekrein; 
PL, phospholipid; and TF, tissue factor.
Figure 2. A cell-based model of coagulation. FXIII indicates fac-
tor XIII; TAFI, thrombin-activatable fibrinolysis inhibitor; and vWF, 
Von Willebrand factor. Adapted with permission from Hoffman 
and Cichon.21 Copyright ©2013, John Wiley & Sons, Inc. Authori-
zation for this adaptation has been obtained both from the owner 
of the copyright in the original work and from the owner of copy-
right in the translation or adaptation.
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from the blood by an intact vessel wall. TF is expressed at 
high levels around the adventitial surface of vessels, as well as 
by epithelial cells, and at sites where bleeding could be cata-
strophic (brain, lungs).23,24 This pattern of TF localization has 
been described as a hemostatic envelope to stop bleeding at 
sites of injury. When the vessel wall is breached, extravascu-
lar TF-bearing cells come in contact with blood components. 
Platelets adhere to collagen and other exposed extracellu-
lar matrix proteins near the site of injury and are partially 
activated.
Thrombin produced on TF-bearing cells then drives sev-
eral positive feedback loops on platelet surfaces during the 
amplification phase of coagulation. If the procoagulant stimu-
lus is sufficiently strong, the amplification process succeeds 
in setting the stage for large-scale platelet-surface thrombin 
generation in the propagation phase of coagulation. This burst 
of thrombin is necessary to stabilize the initial platelet plug 
in a stable fibrin clot. The hemostatic clot is further stabilized 
by activation of thrombin-activatable fibrinolysis inhibitor and 
FXIII. Active thrombin also remains bound within the fibrin 
clot, where it can rapidly cleave additional fibrinogen and 
reinforce the clot structure if it is mechanically or enzymati-
cally disrupted.
Viewed in this way, the intrinsic and extrinsic pathways 
are not redundant as they seem to be in the cascade model. 
Instead, they carry out distinct functions on different cell 
surfaces—each of which depends on thrombin generation. 
The extrinsic pathway acts on TF-bearing cells to produce the 
small, but critical, amounts of thrombin needed for amplifi-
cation of the initial procoagulant signal. Components of the 
intrinsic pathway act on the surface of activated platelets to 
produce large amounts of thrombin required for formation of 
a stable fibrin clot. Thus, there are 2 key points at which a 
NOAC thrombin or FXa inhibitor can act to impair clotting 
(Figure 3): (1) at level of thrombin-driven feedback loops—
thus blocking amplification, and (2) at the level of the burst of 
platelet-surface thrombin generation.
Although thrombin is a critical mediator at each of these 
phases, NOACs that directly target thrombin are mechanis-
tically distinct from NOACs that target thrombin production 
by inhibiting FXa. A direct FXa inhibitor acts to reduce the 
amount of thrombin generated while a direct thrombin inhibi-
tor inhibits the thrombin after it is already formed (Figure 3).
The NOACs are small molecules and have properties that 
are different from the naturally occurring inhibitors of coagu-
lation proteases. The physiological inhibitors, antithrombin 
and tissue factor pathway inhibitor are large proteins, ≈58 kDa 
and 34 to 40 kDa, respectively. Thus, antithrombin is sterically 
hindered from interacting with thrombin that is sequestered 
within a fibrin clot or bound to a cofactor, such as thrombo-
modulin. Likewise, FXa on a platelet surface is relatively pro-
tected from inhibition by either antithrombin or tissue factor 
pathway inhibitor. Thus, the plasma inhibitors are important 
control mechanisms that localize the coagulation reactions to 
specific cell surfaces and prevent thrombin generation from 
occurring in the fluid phase (disseminated intravascular coag-
ulation) or spreading within the vascular tree (thrombosis). 
However, they allow coagulation to proceed on appropriate 
cell surfaces.
By contrast, NOACs can inhibit thrombin and FXa at 
sites on cell surfaces where they are relatively inaccessible 
to the plasma protease inhibitors.25 They can also reach their 
target proteases within the structure of a fibrin clot. Thus, 
NOACs can inhibit coagulation by acting at sites where the 
natural inhibitors are ineffective. However, the activity of 
thrombin can be changed dramatically by binding to dif-
ferent cofactors. For example, thrombin bound to thrombo-
modulin on the surface of healthy endothelial cells cannot 
clot fibrinogen but instead can activate protein C and exert 
an antithrombotic effect. Dabigatran not only inhibits the 
procoagulant effects of thrombin but also inhibits throm-
bin in complex with thrombomodulin,26 thereby reducing 
protein C activation and potentially exerting an unintended 
prothrombotic effect.
In thrombin generation assays, and likely in vivo, the rate 
of thrombin generation is a measure of hemostatic effective-
ness. The rate of thrombin generation reflects both the number 
of functional FXa/Va complexes on platelets and the amount 
of prothrombin available as a substrate for those FXa/Va com-
plexes. The VKAs alter thrombin generation by reducing the 
levels of FIX, FX, and prothrombin. The reduced levels lead 
to less FX available to be activated and less FIXa to active FX; 
Figure 3. The targets of non–vitamin K 
antagonist oral anticoagulants in a cell-
based model of coagulation. Factor Xa 
(Fxa) inhibitors (left) exert anticoagulant 
effects by preventing thrombin genera-
tion during the initiation and propaga-
tion phases. Thrombin inhibitors (right) 
directly inhibit thrombin from cleaving its 
protein substrates during the amplifica-
tion phase and after it is formed in the 
propagation phase. TF indicates tissue 
factor; and vWF, Von Willebrand factor.







1816  Arterioscler Thromb Vasc Biol  October 2017
overall, this reduces the number of FXa/Va complexes. The 
reduced levels of prothrombin further slow the rate of throm-
bin generation. So overall, VKAs predominantly impact the 
propagation phase of thrombin generation.27
In our own data and that of several other workers, dabiga-
tran and other direct thrombin inhibitors seem to have a pri-
mary effect by slowing or blocking the amplification phase 
of coagulation. This delays or prevents large-scale thrombin 
generation. In a thrombin generation assay, this is seen as a 
prolongation of the lag before onset of detectable thrombin 
generation. When the level of thrombin produced exceeds 
some threshold, the burst of platelet-surface thrombin genera-
tion ensues. The activity of the thrombin generated during the 
propagation phase is also blunted by the presence of a throm-
bin inhibitor. However, thrombin is generated at a sufficient 
rate to be detected in the thrombin generation assay. Thus, a 
thrombin inhibitor is most effective as an anticoagulant if it 
can prevent the burst of platelet surface thrombin generation 
from ever getting started. The in vivo reflection of this mecha-
nism is likely that a thrombin inhibitor can prevent coagula-
tion from even being launched at inappropriate sites, yet allow 
coagulation to proceed if the procoagulant stimulus is suffi-
ciently strong.
Direct FXa inhibitors increase the lag phase to a limited 
extent by delaying thrombin generation during the initia-
tion phase. However, their dominant effect is to decrease 
the rate of thrombin generation during propagation by 
inhibiting a fraction of the platelet-surface FXa/Va com-
plexes. The effects of rivaroxaban on thrombin generation 
are shown in Figure 4.
Observations on the Inhibitory  
Properties of NOACs
NOACs Do Not Completely Inhibit 
the Target Protease
The ability of a strong procoagulant stimulus to overcome the 
anticoagulant effect of an inhibitor is inherent in its mech-
anism of action. The free and bound forms of a reversible 
inhibitor (dabigatran in this example) with its target protease 
(thrombin) reach a state of equilibrium. The proportion of the 
thrombin molecules that are in the bound (inhibited) form 
can be calculated from the concentrations of the reactants 
(thrombin and dabigatran) and the affinity of the inhibitor for 
its target protease. The higher the concentration of dabiga-
tran, the greater will be the proportion of the thrombin that is 
inhibited. However, there will always be some thrombin mol-
ecules that are not inhibited. If more thrombin is generated, 
the level of free (active) thrombin will increase at any given 
concentration of dabigatran. Thus, the effect of the inhibitor 
could be overcome if the procoagulant stimulus is sufficiently 
strong and, therefore, the total amount of thrombin generated 
is sufficient to trigger the burst of platelet surface thrombin 
generation.
We speculate that this could be the reason that intracra-
nial bleeding is reported to be lower with some NOACs than 
VKAs.29–31 The brain contains extremely high levels of TF, 
the main initiator of coagulation. Thus, exposure of blood to 
brain tissues could constitute a sufficiently strong stimulus to 
overcome the inhibitory effect of a therapeutic level of NOAC 
anticoagulation.
In addition, the ability of a greater rate/amount of protease 
activation to overcome the effects of a NOAC likely accounts 
for the ability of prothrombin complex concentrates to reverse 
their anticoagulant effect.32 Administration of prothrombin 
complex concentres raises the plasma levels of FVII, FIX, 
FX, and prothrombin and leads to a greater rate of FX and 
prothrombin activation. The increased production of FXa and 
thrombin would increase the amount of active thrombin avail-
able to support hemostasis.
NOAC Inhibition Is Reversible
A key biochemical property of NOACs is their reversibility. 
This is in contrast to the effects of VKAs, UFH, antithrombin, 
and other SERPINs, and α-2-macroglobulin, which are effec-
tively not reversible. Thrombin generation assays also reveal 
a surprising result of the reversible nature of NOAC inhibi-
tion. Because dabigatran blocks the active site of thrombin, it 
blocks all active site functions, including preventing inactiva-
tion by antithrombin and other inhibitors.33 Commonly used 
thrombin generation assays (left panel of Figure 5, assays con-
ducted as in 34) show how much free, that is, active, thrombin 
is present at a given point in time. So the assay detects neither 
thrombin inactivated by antithrombin nor thrombin inhibited 
by dabigatran. Increasing concentrations of dabigatran mark-
edly increase the lag time, with a less dramatic effect on the 
rate of thrombin generation and peak thrombin level attained. 
These effects are seen over a range of dabigatran concentra-
tions attained during anticoagulant in vivo.
By contrast, a modified thrombin generation assay (right 
panel of Figure 5) detects thrombin that has not been perma-
nently inactivated by antithrombin. In this assay, thrombin 
generation is again triggered in platelet-rich plasma contain-
ing different levels of dabigatran. Samples are removed at 
timed intervals and added to an assay mixture containing a 
chromogenic substrate for thrombin. Sampling into the assay 
mixture dilutes all of the plasma components. This results in 
Figure 4. Effect of rivaroxaban on a thrombin generation assay. 
The curves represent the level of thrombin activity triggered 
by 0.5 pmol/L tissue factor in platelet-rich plasma at the indi-
cated concentrations of rivaroxaban. There is a concentration-
dependent decrease in the rate of thrombin generation and a less 
pronounced decrease in the peak thrombin level. Modified with 
permission from Perzborn et al.28 Copyright ©2015, the Authors.
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the dabigatran concentration falling to a level at which the 
equilibrium between free (active) thrombin and bound (inhib-
ited) thrombin favors the free form. Thus, the activity of the 
thrombin that had been reversibly inhibited by dabigatran, but 
protected from inactivation by antithrombin, is revealed. In 
this modified assay, the expected increase in the lag time is 
seen. But one can also see an increase in the amount of throm-
bin that was not inactivated by antithrombin. It is clear that a 
large amount of thrombin has been protected from inactiva-
tion and can express its activity as the dabigatran level falls.26
The in vivo consequences of the reversibility of a coag-
ulation protease inhibitor are not completely clear, but we 
hypothesize the following. The NOACs have short half-lives 
relative to VKAs. Thus, the plasma levels rise and fall between 
doses. This means that the extent of thrombin inhibition rises 
and falls. This effect is exacerbated if more than 1 doses of 
drug are missed. When the drug level falls, the reservoir of 
thrombin that has been sequestered within a fibrin/platelet 
clot can regain activity. Potentially, this thrombin could have 
procoagulant activity and contribute to rebound hypercoagu-
lability if the dabigatran level falls sufficiently. However, this 
thrombin can now be inactivated by the physiological inhibi-
tors, including antithrombin. If the fall in dabigatran levels is 
slow, antithrombin inactivation might prevent the accumula-
tion of sufficient free thrombin to have any biological effect. 
Thus, the overall clinical effect in vivo is difficult to predict.
The same reversibility would be seen for FXa inhibitors.25 
Because much less FX (on a molar basis) is activated during 
hemostasis than thrombin, we would not expect as large a res-
ervoir of FXa activity to be revealed as the levels of an FXa 
inhibitor fall. However, to our knowledge, the reactivation of 
FXa activity on platelet surfaces or within a fibrin clot has not 
been studied.
In summary, the biochemical properties of the new gen-
eration of reversible active site inhibitors of coagulation pro-
teases are significantly different from the commonly used 
anticoagulants to which we are accustomed. The properties of 
the NOACs as therapeutic agents remain to be fully explored. 
However, a consideration of their biochemical features can 
help us understand their pharmacological effects and provide 
a rationale for therapeutic strategies using these agents.
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Highlights
• Inhibiting one protease is much less effective at inhibiting coagulation than is inhibiting at multiple steps. Thus, non–vitamin K antagonist oral 
anticoagulants (NOACs) are less able to achieve intensive anticoagulation than are vitamin K antagonists or heparin. The more linear relation-
ship between drug level and inhibitory effect makes it easier to reach the sweet spot in the desired intensity of NOAC anticoagulation. This 
partially accounts for why the NOACs are safer than vitamin K antagonists.
• NOACs can reach their target proteases at sites that naturally occurring plasma protease inhibitors, such as antithrombin, cannot, including on 
the platelet surfaces and within a fibrin clot.
• NOACs are reversible inhibitors. When the drug level falls, the drug dissociates from its target and active protease is released. In addition, the 
presence of a NOAC prevents antithrombin from inactivating the protease. Thus, there is the possibility of a rebound in procoagulant activity if 
the drug is abruptly terminated.
• The effects of NOACs can be overcome by increasing the amount of protease production. At any given drug level of drug, there will be a fixed 
proportion of the target protease that is not inhibited. When production of the target protease is increased, the amount of active protease will 
also be increased. This property may contribute to the safety of NOACs and their potential reversibility by coagulation factor concentrates.
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